Oral Testosterone Undecanoate Capsules combined with Qilin Pills for late-onset hypogonadism in males.
- Author:
Jun-Biao MAO
1
;
Xiao-Gang CHEN
1
;
Ding-Wen GUI
1
;
Wei PENG
1
;
Jie ZHENG
1
Author Information
1. Department of Urology, Huangshi Central Hospital / The Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei 435000, China.
- Publication Type:Journal Article
- Keywords:
Testosterone Undecanoate Capsules;
late-onset hypogonadism;
Qilin Pills
- MeSH:
Androgens;
administration & dosage;
adverse effects;
Capsules;
Drug Therapy, Combination;
adverse effects;
Drugs, Chinese Herbal;
administration & dosage;
adverse effects;
Humans;
Hypogonadism;
blood;
drug therapy;
Male;
Middle Aged;
Testosterone;
administration & dosage;
adverse effects;
analogs & derivatives;
blood
- From:
National Journal of Andrology
2017;23(5):455-458
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical effects of oral Testosterone Undecanoate Capsules (TUC) combined with Qilin Pills (QLP) on late-onset hypogonadism (LOH) in men.
METHODS:Sixty-three LOH patients meeting the inclusion criteria were randomly divided into a control group (aged ［48.4 ± 6.2］ yr, n = 32) and an experimental group (aged ［47.2 ± 5.6］ yr, n = 31) to be treated with oral TUC (80 mg, qd) and TUC + QLP (6g, tid), respectively, both for 3 months. Comparisons were made between the two groups of patients in the IIEF-5 scores, total testosterone (TT) levels, and scores in the Aging Males' Symptoms (AMS) scale before and after treatment.
RESULTS:After treatment, the patients of the experimental group, as compared with the controls, showed a significantly increased IIEF-5 score (21.7 ± 5.8 vs 15.9 ± 4.7, P <0.05) and TT level (［16.7 ± 2.2］ vs ［13.1 ± 2.8］ nmol/L, P <0.05), but a decreased AMS score (20.7 ± 5.7 vs 31.3±6.5, P <0.05).
CONCLUSIONS:TUC combined with Qilin Pills has a better effect and a lower rate of adverse reactions than TUC used alone in the treatment of late-onset hypogonadism in males.
